Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-12-11
2007-12-11
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
10390032
ABSTRACT:
The present invention relates, in general, to the treatment of estrogen-dependent diseases and disorders and, in particular, to a method of treating estrogen-dependent cancers, particularly breast cancer, with antiestrogens.
REFERENCES:
patent: 3341537 (1967-09-01), Richardson et al.
patent: 3493606 (1970-02-01), Richardson
patent: 3637856 (1972-01-01), Landquist et al.
patent: 4198435 (1980-04-01), Richardson
patent: 4206234 (1980-06-01), Richardson
patent: 4307111 (1981-12-01), Crawley
patent: 4536516 (1985-08-01), Harper et al.
patent: 4623660 (1986-11-01), Richardson
patent: 4760053 (1988-07-01), Labrie
patent: 4803227 (1989-02-01), Brandes et al.
patent: 4851433 (1989-07-01), Kraus
patent: 4859695 (1989-08-01), McKissick et al.
patent: 4894373 (1990-01-01), Young
patent: 4960937 (1990-10-01), Woschina et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5119827 (1992-06-01), Osborne et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5393785 (1995-02-01), Labrie et al.
patent: 5410080 (1995-04-01), Bitonti et al.
patent: 5455275 (1995-10-01), Fontana
patent: 5491173 (1996-02-01), Toivola et al.
patent: 5550164 (1996-08-01), Fontana
patent: 5681835 (1997-10-01), Willson
patent: 5877219 (1999-03-01), Wilson
patent: 6207716 (2001-03-01), Willson
patent: 0 054 168 (1982-06-01), None
patent: 0 095 875 (1983-12-01), None
patent: 0 178 862 (1986-04-01), None
patent: 0 272 330 (1988-06-01), None
patent: 0 589 039 (1994-03-01), None
patent: 1029221 (1966-05-01), None
patent: 1064629 (1967-04-01), None
patent: 1079747 (1967-08-01), None
patent: 2 058 061 (1981-04-01), None
patent: WO 92/04310 (1992-03-01), None
patent: WO 92/06068 (1992-04-01), None
patent: WO 92/19585 (1992-11-01), None
patent: WO 94/23708 (1994-10-01), None
Wilson, T. M. et al “A non-steroidal estrogen with functional selectivity for bone over uterus in rats” J. Med. Chem. (1994) vol. 3 pp. 1550-1552.
Willson, T. M., et al; “Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone”;Endocrinology; vol. 138, No. 9; pp. 3901-3911 (1997).
Shao, W., et al.; Coactivator AIB1 links estrogen receptor transcriptional activity and stability;PNAS; vol. 101, No. 32; pp. 11599-11604 (2004).
van Duijn, Menopause and the brain, J Psychosom Obstet Gynaecol. Jun. 1997;18(2):121-5 (Abstract).
Schneider et al, Can estrogens prevent neurodegeneration?, Drugs Aging. Aug. 1997;11(2):87-95 (Abstract).
Klein et al, Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 1994;92:289-95; discussion 295-7 (Abstract).
Smith et al, Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Opthalmol. May 1997;25 Suppl 1:S13-5 (Abstract).
Fantl et al, Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First rept of the Hormones and Urogenital Ther. Com., Obstet Gynecol. Jan. 1994;83(1):12-8 (Abstract).
Elia et al, Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence, Obstet Gynecol Surv. Jul. 1993;48(7):507-17 (Abstract).
Ferrara et al, Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance status. The Rancho Bernardo Study, 1984-1987, Diabetes Care, Feb. 1995;18(2):220-5 (Abstract).
Song et al, Molecular characterization of a testis-specific estrogen sulfotransferase and aberrant liver expression in obese and diabetogenic C57BL/KsJ-db/db mice, Endocrinology. Jun. 1995; 136(6):2477-84 (Abstract).
Bracken et al, Conception delay after oral contracep. use: the effect of estrogen dose, Fertil Steril. Jan. 1990;53(1):21-7 (Abstract).
Jequier, Conception in the resistant ovary syndrome occurring during hormone replacement therapy: a report of 2 cases, Aust N Z J Obstet Gynaecol. May 1990;30(2):176-8 (Abstract).
Pavlik et al, “Resistance to Tamoxifen with Persisting Sensitivity to Estrogen: Possible Mediation by Excessive Antiestrogen Binding Site Activity”, Cancer Research 52:4106-4112 (1992).
Nicolaus, “Symbiotic Approach to Drug Design” Decision Making in Drug Research, edited by Franz Gross, Raven Press, New York, pp. 173-186 (1983).
Hartmann et al, “Antiestrogen resistance in ER positive breast cancer cells”, Breast Cancer Res. Treat. 31(2-3):301-307 (1994)—Abstract.
deGraffenried et al, “Regulation of the estrogen receptor alpha minimal promoter by Spl, USF-1 and ERalpha”, Breast Cancer Res. Treat. 85(2):111-120 (2004) abstract.
Willson et al, “3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steriodal Estrogen with Functional Selectivity for Bone over Uterus in Rats”, J. Med. Chem. 37:1550-1552 (1994).
Howell et al, “Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer”, The Lancet 345:29-30 (1995).
Buzdar et al, “Phase II Evaluation of Ly156758 in Metastatic Breast Cancer”, Oncology 45:344-345 (1988).
Tzukerman et al, “Human Estrogen Receptor Transactivational Capacity Is Determined by both Cellular and Promoter Context and Mediated by Two Functionally Distinct Intramolecular Regions”, Molecular Endocrinology 8(1):21-30 (1994).
McDonnell and Norris, “Analysis of the Molecular Pharmacology of Estrogen Receptor Agonists and Antagonists Provides Insights into the Mechanism of Action of Estrogen in Bone”, Osteoporosis Int. Suppl. 1:S0-S00 (1997).
McDonnell et al, “Analysis of Estrogen Receptor Function in Vitro Reveals Three Distinct Classes of Antiestrogens”, Molecular Endocrinology 9(6):659-669 (1995).
Jordan and Murphy, “Endocrine Pharmacology of Antiestrogens as Antitumor Agents”, Endocrine Reviews 11(4):578-610 (1990).
Lerner and Jordan, “Development of Antiestrogens and Their Use in Breast Cancer: Eighth Cain Memorial Award Lecture”, Cancer Research 50:4177-4189 (1990).
Jordan et al, “Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens in Vitro”, Molecular Pharmacology 26:272-278 (1984).
Jordan et al, “A monohydroxylated Metabolite of Tamoxifen with Potent Antioestrogenic Activity”, J. Endocr. 75:305-316 (1977).
Jordan and Gosden, Importance of the Alkylaminoethoxy Side-Chain For The Estrogenic and Antiestrogenic Actions of Tamoxifen and Trioxifene in the Immature Rat Uterus Moleculear and Cellular Endocrinology 27:291-306 (1982).
Jarman et al, “Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts”, Anti-Cancer Drug Design 1:259-268 (1986).
Murphy and Jordan, “Structural Components Necessary For The Antiestrogenic Activity Of Tamoxifen”, J. Steroid Biochem. 34(1-6):407-411 (1989).
Harper and Walpole, “Contrasting Endocrine Activities ofcisandtransIsomers in a Series of Substituted Triphenylethylenes”, Nature 5057:87 (1966).
Jordan et al, “Geometric Isomers of Substituted Triphenylethylenes and Antiestrogen Action”, Endocrinology 108(4):1353-1361 (1981).
Katzenellenbogen et al, “Bioactivities, Estrogen Receptor Interactions, and Plasminogen Activator-inducing Activities of Tamoxifen and Hydroxy-tamoxifen Isomers in MCF-7 Human Breast Cells”, Cancer Research 44:112-119 (1984).
Katzenellenbogen et al, “Facile Geometric Isomerization of Phenolic Non-Steroidal Estrogens and Antiestrogens: Limitations To The Interpretation Of Experiments Characterizing The Activity Of Individual Isomers”, J. Steroid Biochem. 22(5):589-596 (1985).
McCague et al, “Synthesis and Estrogen Receptor Binding of 6,7-Dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy]phenyl]-5H-benzocycloheptene, a Nonisomerizable Analogue of Tamoxifen. X-ray Crystallographic Studies”, J. Me
Connor Caroline
McDonnell Donald P.
Norris John
Wijayaratne Ashini
Duke University
Maier Leigh C.
LandOfFree
Method of preventing or treating estrogen-dependent diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing or treating estrogen-dependent diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing or treating estrogen-dependent diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853235